HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help stop tumor growth. A number of classes of anti estrogenic agents available for patients with early, advanced, or metastatic breast cancer includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader. The total incident population of breast cancer in the 7MM is expected to rise to 698,212 in 2030, during the study period [2017–2030]. Among the 7MM, the US accounts for the 80.51% USD of the overall market size of ER-positive/HER2-negative Breast Cancer in 2017. For more details visit: https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-market-insights